{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:35:05Z","timestamp":1783740905365,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10637-022-01254-2","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T05:02:40Z","timestamp":1651554160000},"page":"854-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Autoimmune hemolytic anemia in patients with relapsed Hodgkin\u2019s lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1"],"prefix":"10.1007","volume":"40","author":[{"given":"Yiming","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"1254_CR1","doi-asserted-by":"publisher","unstructured":"Dhillon S (2021) Penpulimab: First approval. Drugs 81:2159\u20132166. https:\/\/doi.org\/10.1007\/s40265-021-01640-9","DOI":"10.1007\/s40265-021-01640-9"},{"key":"1254_CR2","doi-asserted-by":"publisher","unstructured":"Song Y, Zhou K, Jin C et al (2021) A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL) [abstract no. 7529]. J Clin Oncol 39:7529. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.7529","DOI":"10.1200\/JCO.2021.39.15_suppl.7529"},{"key":"1254_CR3","doi-asserted-by":"publisher","first-page":"A481","DOI":"10.1136\/jitc-2020-SITC2020.0804","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, Wang W, Zou Q et al (2020) A phase II study of the anti-programmed cell death-1 (pd-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (npc) who had progressed after two or more lines of chemotherapy. J Immunother Cancer 8:A481. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0804","journal-title":"J Immunother Cancer"},{"key":"1254_CR4","doi-asserted-by":"publisher","unstructured":"Han B, Chen J, Wang Z et al (2021) Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous nonsmall-cell lung cancer [abstract no. e21072]. J Clin Oncol 39(15):e21072. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e21072","DOI":"10.1200\/JCO.2021.39.15_suppl.e21072"},{"key":"1254_CR5","doi-asserted-by":"publisher","unstructured":"Singh R, Sheikh S, Pallagatti S et al (2015) Lymphocyte depleted Hodgkin's lymphoma presented with haemolytic anemia: A case report and literature review. J Maxillofac Oral Surg 14:317\u2013322. https:\/\/doi.org\/10.1007\/s12663-013-0528-1","DOI":"10.1007\/s12663-013-0528-1"},{"key":"1254_CR6","doi-asserted-by":"publisher","unstructured":"Tardy MP, Gastaud L, Boscagli A, Peyrade F, Gallamini A, Thyss A (2017) Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report. Hematol Oncol 35:875\u2013877. https:\/\/doi.org\/10.1002\/hon.2338.","DOI":"10.1002\/hon.2338"},{"key":"1254_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","volume":"101","author":"G Paola","year":"2021","unstructured":"Paola G, Kristen M, Satish S, Brahmer JR, Naik RP (2021) Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review. Ann Hematol 101:1\u201310. https:\/\/doi.org\/10.1007\/s00277-021-04690-x","journal-title":"Ann Hematol"},{"key":"1254_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245. https:\/\/doi.org\/10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"1254_CR9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Pei Y, Luo J, Huang Z, Yu J, Meng X (2020) Looking for the Optimal PD-1\/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. Front Immunol 11:1088. https:\/\/doi.org\/10.3389\/fimmu.2020.01088","journal-title":"Front Immunol"},{"key":"1254_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.seminhematol.2015.05.001","volume":"52","author":"W Barcellini","year":"2015","unstructured":"Barcellini W (2015) Immune Hemolysis: Diagnosis and Treatment Recommendations. Semin Hematol 52:304\u2013312. https:\/\/doi.org\/10.1053\/j.seminhematol.2015.05.001","journal-title":"Semin Hematol"},{"key":"1254_CR11","doi-asserted-by":"publisher","unstructured":"Jain NA, Zhao S, Wei L et al (2020) Association between RBC antigen allo-antibodies and immune-related adverse events during immune checkpoint inhibitor treatment for advanced cancers. Cancer Manag Res 12:11743\u201311749. https:\/\/doi.org\/10.2147\/CMAR.S264166","DOI":"10.2147\/CMAR.S264166"},{"key":"1254_CR12","doi-asserted-by":"publisher","unstructured":"Ogawa K, Ito J, Fujimoto D et al (2018) Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. Invest New Drugs 36:509\u2013512. https:\/\/doi.org\/10.1007\/s10637-018-0561-5","DOI":"10.1007\/s10637-018-0561-5"},{"key":"1254_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13187","volume":"102","author":"GE Tanios","year":"2019","unstructured":"Tanios GE, Doley PB, Munker R (2019) Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102:157\u2013162. https:\/\/doi.org\/10.1111\/ejh.13187","journal-title":"Eur J Haematol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01254-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:47:12Z","timestamp":1678510032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01254-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1254"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01254-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. The Qingdao Municipal Hospital Research Ethics Committee has confirmed that no ethical approval is required.v","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This paper has been published with the consent of patients and their families.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Supplement Fig. A, B and C.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}